Scientists believe the proteins (PLAUR, SERPINA3, CRIM1, DDR1 and LTBP2), that play key roles in the development of diseases such as cancer and inflammation, may also contribute to the risk of dying.
Researchers have created an artificial intelligence model that can identify which mutations in human proteins are most likely to cause disease, even when those mutations have never been seen before in any person.
Patients with the deadliest form of brain cancer, glioblastoma, who received MRI-guided focused ultrasound with standard-of-care chemotherapy had a nearly 40% increase in overall survival in a landmark trial of 34 patients led by University of Maryland School of Medicine (UMSOM) researchers.
Transmural Systems’ Telltale guide wire aims to prevent coronary obstruction by modifying the ‘leaflet’ tissue in high-risk patients undergoing TAVR.
The Centers for Medicare and Medicaid Services (CMS) has provided a major reimbursement update for cardiac ablation technologies.
CeriBell (Nasdaq:CBLL) announced today that it received FDA 510(k) clearance for its next-generation Clarity algorithm.
An emerging artificial intelligence-powered system developed at Penn Medicine has tripled the speed of fax processing and cut a full week off the new patient intake process—freeing up thousands of staff hours. The system, called coordn8, was created by the Penn Medicine Center for Health Care Transformation and Innovation (CHTI) and is detailed in a new paper published this week in NEJM Catalyst.
PARAMUS, N.J., Nov. 25, 2025 /PRNewswire/ — Regenity Biosciences, a global leader in regenerative medicine and Linden Capital Partners portfolio company, today announced its 63rd FDA 510(k) clearance for DuraMatrix® Repair – Collagen Dura Regeneration Membrane, a resorbable membrane composed of highly purified Type I and Type III bovine collagen for the repair of dura mater defects during neurosurgery.
Researchers at Washington University School of Medicine in St. Louis, along with collaborators at Northwestern University, have developed a noninvasive approach to treat one of the most aggressive and deadly brain cancers.
Recor Medical said today that it secured Medicare approval, granting coverage for the company’s RADIANCE CED study.